As RB has EZH2 overexpression and pharmacological inhibition of EZH2 in human RB cells shows a clear anticancer activity, preclinical studies on EZH2 inhibitors in RB tumor models will be required to further strengthen a possibility of clinical trials for these compounds in RB treatment. This evidence concerns the gene EZH2 and retinoblastoma.